EX-99.2 3 catx-ex99_2.htm EX-99.2

Slide 1

Investor Call ASCO 2025 Presentation

Slide 2

 

Slide 3

Developing the Next Generation of Targeted Therapies

Slide 4

 

Slide 5

Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment Perspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT

Slide 6

Neuroendocrine Tumors: VMT-⍺-NET

Slide 7

 

Slide 8

NETs Trials

Slide 9

Interim safety and efficacy data of [212Pb]VMT-α-NET in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs)

Slide 10

Key Takeaway Points/Conclusions

Slide 11

Trial Design: [212Pb]VMT-⍺-NET Phase 1/2a For Neuroendocrine Tumors

Slide 12

Patient Disposition

Slide 13

Baseline Patient Characteristics

Slide 14

[212Pb]VMT-α-NET Was Well Tolerated

Slide 15

Seven Patients Experienced Grade 1 Blood Creatinine Increase

Slide 16

Mild and Generally Transient Blood Creatinine Increase

Slide 17

ASCO-GI 2025: Anti-Tumor Activity

Slide 18

Update at ASCO: Anti-Tumor Activity

Slide 19

ASCO-GI 2025: Eight of Nine Patients Remain on Study

Slide 20

Updated at ASCO 2025: Seven of Nine Patients Remain on Study

Slide 21

ASCO-GI 2025: Signal of Sustained Anti-Tumor Activity

Slide 22

Updated at ASCO 2025: Signal of Sustained Anti-Tumor Activity

Slide 23

Patient (103-105) with Confirmed PR After [212Pb]VMT-α-NET

Slide 24

Next steps and concluding remarks

Slide 25

 

Slide 26

Q & A